Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Description

To learn if a process called neuromodulation can help to improve pain due to CIP

Conditions

Neuropathy;Peripheral

Talk to us

Study Overview

On this page

Study Details

Study overview

To learn if a process called neuromodulation can help to improve pain due to CIP

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Condition
Neuropathy;Peripheral
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to understand and the willingness to sign a written informed consent document
  • * Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
  • * Patients seen at Pain Management Center at MD Anderson Cancer Center
  • * Patient ages greater or equal to 18 years but less than or equal to 85 years
  • * Patients with cognitive dysfunction
  • * Patient with recent history (\<6 months) of drug or alcohol abuse
  • * Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
  • * Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Saba Javed, M D, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-04-01